After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this
Tag: Difei Yang
Associated Capital Group (AC) Gets a Hold Rating from Mizuho Securities
In a report issued on March 30, Difei Yang from Mizuho Securities maintained a Hold rating on Associated Capital Group
Mizuho Securities Sticks to Their Buy Rating for Zogenix (ZGNX)
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Zogenix (ZGNX – Research Report),
Selecta Biosciences (SELB) Received its Third Buy in a Row
After Canaccord Genuity and Needham gave Selecta Biosciences (NASDAQ: SELB) a Buy rating last month, the company received another Buy,
Aerie Pharma (AERI) Received its Third Buy in a Row
After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xeris Pharmaceuticals (NASDAQ: XERS), Spero Therapeutics (NASDAQ: SPRO) and aTyr Pharma (NASDAQ: LIFE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research
Mizuho Securities Maintains a Buy Rating on FibroGen (FGEN)
Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN – Research Report) today and set a price